SEC Form 4 · accession 0001662426-26-000004
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott W Morrison
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2026 | M | 2,954 | — | A | 7,638 | D | |
| Common StockF2 | holding | — | — | — | 6,016 | I | By Morrison-Minton Family 2004 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Jun 12, 2026 | M | 2,954 | D | — | — | Common Stock | 2,954 | 0 | D |
Explanation of responses
- F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust.
- F3Each RSU represents a contingent right to receive one share of the Company's common stock.
- F4RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.